Sol-Gel Technologies Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of September 2026, with a specific report date of September 17, 2026. Sol-Gel Technologies Ltd., a foreign private issuer based in Ness Ziona, Israel, filed this report to disclose a material corporate development regarding its clinical trial progress.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or quantitative financial data.
Material Changes
The primary material change disclosed is a clinical milestone. On September 17, 2026, the Company announced the "last patient last visit" (LPLV) in the pivotal Phase 3 clinical trial of its drug candidate SGT-610 for the treatment of Gorlin Syndrome.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the clinical milestone. The filing incorporates a press release (Exhibit 99.1) by reference into the Company's Registration Statements on Form S-8 and Form F-3. No specific financial guidance, risk factors, or contingencies are detailed within the text of this specific Form 6-K.
Key Facts for Investor Verification
- Verify the full text of the press release (Exhibit 99.1) for details on the SGT-610 Phase 3 trial results and next steps.
- Confirm the timeline for the final data readout and potential regulatory submission following the LPLV milestone.
- Review the Company's most recent Form 20-F for current financial position, cash runway, and liquidity status, as this filing does not contain such data.